SMTL ID : 8i7z.1 (1 other biounit)

The crystal structure of human abl1 kinase domain in complex with ABL1-B5

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.25 Å

Oligo State

monomer

Ligands

1 x 6CI: 5-[3-(2-methoxy-5-oxidanyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethyl-pyridine-3-carboxamide(Non-covalent)

6CI.1: 13 residues within 4Å: Chain A: L.20, V.28, A.41, V.42, K.43, T.87, E.88, F.89, M.90, G.93, N.94, L.142, F.154 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:L.20, A:V.28, A:A.41, A:L.142, A:L.142 Hydrogen bonds: A:T.87, A:E.88, A:M.90, A:N.94, A:N.94

1 x BAL: BETA-ALANINE(Covalent)

BAL.2: 5 residues within 4Å: Chain A: K.43, M.50, E.58, I.85, F.154 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:F.154

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Sun, J. et al., Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies. J Adv Res (2024)

Release Date

2024-10-23

Peptides

Tyrosine-protein kinase ABL1: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase ABL1

Related Entries With Identical Sequence